Teva Introduces Nicardipine HCl Injection In The United States; First Alternative To Cardene(R) I.V.
26 Dec 2008
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced the introduction of Nicardipine Hydrochloride Injection, 2.5 mg/mL, which is AP-rated to EKR Therapeutics’ hypertension treatment Cardene® I.V. Teva’s product is the first alternative to the brand product, which had annual sales of approximately $181 million in the United States for the twelve months ended June 30, 2008, according to IMS sales data.
Teva is manufacturing Read the rest of this entry »